Considerations for generic oncology FDG-PET/CT protocol preparation in drug development

IDrugs

Volumn 10, Issue 11, 2007, Pages 791-796

  Hallett, W A ^a   Maguire, R P ^b   McCarthy, T J ^b   Schmidt, M E ^c   Young, H ^d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b PFIZER INC   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Biomarker; Cancer; Drug development; FDG PET; FDG PET CT; Imaging; Standardization; Tumor response

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; TRACER;

ACCURACY; CALIBRATION; CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DATA ANALYSIS; DECISION MAKING; DIAGNOSTIC IMAGING; DRUG DEVELOPMENT; DRUG INDUSTRY; IMAGE ANALYSIS; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FLUORODEOXYGLUCOSE F18; HUMANS; MODELS, STATISTICAL; NEOPLASMS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RESEARCH DESIGN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35648992092     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)